Market Research Logo

Rectal Cancer - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Rectal Cancer Overview
Therapeutics Development
Pipeline Products for Rectal Cancer - Overview
Pipeline Products for Rectal Cancer - Comparative Analysis
Rectal Cancer - Therapeutics under Development by Companies
Rectal Cancer - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Rectal Cancer - Products under Development by Companies
Rectal Cancer - Companies Involved in Therapeutics Development
AbbVie Inc.
Cerulean Pharma, Inc.
Hanwha Chemical Corporation
Incuron, LLC
Karyopharm Therapeutics, Inc.
Nanobiotix
Peregrine Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Rectal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
bavituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRLX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganetespib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HD-204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mepacrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NBTXR-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
veliparib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ziv-aflibercept (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rectal Cancer - Recent Pipeline Updates
Rectal Cancer - Dormant Projects
Rectal Cancer - Product Development Milestones
Featured News & Press Releases
Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Rectal Cancer, H2 2015
Number of Products under Development for Rectal Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Rectal Cancer - Pipeline by AbbVie Inc., H2 2015
Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015
Rectal Cancer - Pipeline by Hanwha Chemical Corporation, H2 2015
Rectal Cancer - Pipeline by Incuron, LLC, H2 2015
Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Rectal Cancer - Pipeline by Nanobiotix, H2 2015
Rectal Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Rectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Rectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Rectal Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Rectal Cancer - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Rectal Cancer, H2 2015 7
Number of Products under Development for Rectal Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Top 10 Targets, H2 2015 23
Number of Products by Stage and Top 10 Targets, H2 2015 23
Number of Products by Top 10 Mechanism of Actions, H2 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 25
Number of Products by Top 10 Routes of Administration, H2 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 27
Number of Products by Top 10 Molecule Types, H2 2015 29
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Rectal Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Rectal Cancer - Pipeline Review, H2 2015’, provides an overview of the Rectal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;